Erwin Sablon

USPTO Granted Patents = 12 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 75(Granted Patents)

Location History:

Opwijk, BE (1999)
Merchtem, BE (2002 - 2017)
Mechelen, BE (2019)

Company Filing History:

N.v. Innogenetics S.a.

Years Active: 1999-2019

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10196673 - Isolation of nucleic acids (2019-02-05),

2. 9725522 - Pulmonary administration of immunoglobulin single variable domains and constructs thereof (2017-08-08),

3. 9320792 - Pulmonary administration of immunoglobulin single variable domains and constructs thereof (2016-04-26),

4. 8124747 - HCV clade and prototype sequences thereof (2012-02-28),

5. 7935490 - Immunodiagnostic assays using reducing agents (2011-05-03),

6. 7314925 - Constructs and methods for expression of recombinant HCV envelope proteins (2008-01-01),

7. 7238356 - Core-glycosylated HCV envelope proteins (2007-07-03),

8. 7196183 - Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent (2007-03-27),

9. 7048930 - Expression of core-glycosylated HCV envelope proteins in yeast (2006-05-23),

10. 6830752 - Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders (2004-12-14),

11. 6350860 - Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders (2002-02-26),

12. 5891679 - TNF-alpha muteins and a process for preparing them (1999-04-06),

Title: The Innovative Journey of Erwin Sablon

Introduction

Erwin Sablon, an influential inventor based in Merchtem, Belgium, has made significant contributions to the field of biotechnology. With a portfolio of 12 patents, his work focuses on advancing methods for analyzing and processing biological samples, with applications in diagnostics and therapeutic delivery systems.

Latest Patents

Among his latest patents, one notable invention is centered on the isolation of nucleic acids. This innovation presents improved compositions and methods that liberate nucleic acids from biological samples, facilitating direct downstream processing within microfluidic systems. These developments are crucial for diagnosing, staging, and characterizing various biological conditions effectively.

Another important patent by Sablon pertains to the pulmonary administration of immunoglobulin single variable domains. This invention details methods for delivering protein therapeutic molecules via various routes, such as orally and through inhalation, while preventing their inactivation. It particularly explores the use of VHH polypeptides derived from Camelidae antibodies, focusing on their systemic delivery through pulmonary tissue and their therapeutic uses against anti-IgE molecules.

Career Highlights

Erwin Sablon has built a commendable career, contributing his expertise to companies such as Innogenetics N.V. and Ablynx N.V. His experience in these organizations has allowed him to develop cutting-edge technologies that enhance medical and therapeutic protocols.

Collaborations

Throughout his career, Sablon has collaborated with esteemed colleagues, including Erik Depla and Fons Bosman. These professional relationships have fostered a dynamic environment for innovation, leading to groundbreaking developments in the field of biotechnology.

Conclusion

Erwin Sablon's inventive prowess and dedication to advancing medical technologies have established him as a notable figure in his industry. His patents reflect a commitment to innovation that not only enhances scientific understanding but also provides practical solutions for pressing medical challenges. As he continues to explore new frontiers in biotechnology, Sablon remains a significant contributor to the evolution of healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.